Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 353

recruiting
3 967
countries
28
conditions
2 124

10 514 trials match your criteria

Study on Sodium Thiosulfate to Prevent Hearing Loss in Patients with Head and Neck Cancer Receiving Cisplatin Treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Thiosulfate

Sickle cell anaemia

Not yet recruiting

Study on the Effectiveness and Safety of Exa-cel for Adolescents and Adults with Severe Sickle Cell Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan

Prostate cancer

Not yet recruiting

Evaluation of [99mTc]PSMA I&S PET‑Guided Navigation with Electromagnetic Tracking in miN1 Prostate Cancer Patients Undergoing Radio‑Guided Surgery

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:[99MTC]PSMA I&S

Clesrovimab vs Sodium Chloride for Reducing RSV and Other Respiratory Pathogen Shedding in Healthy Infants

Registered drug
Countries:GreeceGreece
  • Participants:0–17 years · Healthy volunteers
  • Substances:Clesrovimab

Interstitial lung disease+1

Not yet recruiting

Safety and Efficacy of Mirivadelgat Compared with Placebo in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Mirivadelgat
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Febuxostat Hemihydrate

Breast cancer

Not yet recruiting

Discontinuation of anti‑HER2 therapy guided by ctDNA in patients with HER2‑positive metastatic breast cancer receiving pertuzumab and trastuzumab

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab

Transplant rejection

Not yet recruiting

Evaluating mezagitamab in adults with late antibody-mediated rejection after kidney transplant

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mezagitamab

Secondary immunodeficiency

Not yet recruiting

Study of Human Normal Immunoglobulin in Adults with Secondary Immune Deficiency after CAR T‑cell or T‑cell Redirecting Therapy for Hematologic Malignancies

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Piclidenoson

Osimertinib and drug combination in metastatic non‑small cell lung cancer with targetable genomic driver alterations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib

Thrombosis prophylaxis

Not yet recruiting

Randomized trial of standard vs high-dose enoxaparin and sodium chloride for preventing clots in critically ill ICU patients at high risk of thrombosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.